Health Care [ 8/12 ] | Biotechnology [ 34/74 ]
NASDAQ | Common Stock
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A.
The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy.
It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers.
The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares TradingS. A.
The company was incorporated in 1996 and is based in San Rafael, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 20, 25 | 0.92 Increased by +411.11% | 0.74 Increased by +24.56% |
| Oct 29, 24 | 0.55 Increased by +161.90% | 0.52 Increased by +5.77% |
| Aug 5, 24 | 0.56 Increased by +93.10% | 0.35 Increased by +60.00% |
| Apr 24, 24 | 0.46 Increased by +70.37% | 0.35 Increased by +31.43% |
| Feb 22, 24 | 0.18 Increased by +13.95 K% | 0.23 Decreased by -21.74% |
| Nov 1, 23 | 0.21 Increased by +625.00% | 0.23 Decreased by -8.70% |
| Jul 31, 23 | 0.29 Increased by +93.33% | 0.23 Increased by +26.09% |
| Apr 26, 23 | 0.27 Increased by +50.00% | 0.18 Increased by +50.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 747.31 M Increased by +15.65% | 124.94 M Increased by +513.22% | Increased by +16.72% Increased by +430.25% |
| Sep 30, 24 | 745.74 M Increased by +27.27% | 106.08 M Increased by +162.72% | Increased by +14.22% Increased by +106.43% |
| Jun 30, 24 | 708.66 M Increased by +19.18% | 107.17 M Increased by +91.25% | Increased by +15.12% Increased by +60.46% |
| Mar 31, 24 | 648.83 M Increased by +9.43% | 88.66 M Increased by +74.35% | Increased by +13.66% Increased by +59.33% |
| Dec 31, 23 | 646.21 M Increased by +20.22% | 20.38 M Increased by +8.28 K% | Increased by +3.15% Increased by +6.91 K% |
| Sep 30, 23 | 585.97 M Increased by +15.95% | 40.38 M Increased by +707.01% | Increased by +6.89% Increased by +623.49% |
| Jun 30, 23 | 594.60 M Increased by +11.39% | 56.04 M Increased by +102.57% | Increased by +9.42% Increased by +81.86% |
| Mar 31, 23 | 592.95 M Increased by +14.17% | 50.85 M Decreased by -57.90% | Increased by +8.58% Decreased by -63.13% |